Francesco De Rubertis
Francesco De Rubertis was appointed in a total of 16 companies and resigned from 6 of these appointments.
Role
Director
Country Of Residence
Switzerland
Nationality
Italian
Date of Birth
January 1970
Occupation
Investor
Active
3
Resigned
6
Dissolved
6
Other
0
Total
16
Companies
| Company | Timeline | Status | |
| Aldena Therapeutics (UK) Ltd Director • Investor | 7 Dec 2022←1 Year 1 Month→27 Jan 2024 | Active | |
| Kaerus Bioscience Limited Director • Investor | 25 Jun 2021←4 Years→Current | Active | |
| Levicept Ltd Director • Investor | 17 Nov 2020←5 Years→Current | Active | |
| Ultrahuman Nine Limited Director • Investor | 13 Nov 2020←4 Years→7 Jun 2025 | Dissolved | |
| Ottimo Pharma Limited Director • Investor | 13 Nov 2020←5 Years→Current | Active | |
| Ultrahuman Fourteen Limited Director • Investor | 13 Nov 2020←4 Years→12 Nov 2024 | Dissolved | |
| Ultrahuman Seven Limited Director • Investor | 13 Nov 2020←4 Years→28 Apr 2025 | Dissolved | |
| Ultrahuman Ten Limited Director • Investor | 13 Nov 2020←4 Years→10 Jun 2025 | Dissolved | |
| Ultrahuman Thirteen Limited Director • Investor | 13 Nov 2020←5 Years→Current | Liquidation | |
| Ultrahuman Twelve Limited Director • Investor | 13 Nov 2020←4 Years→10 Mar 2025 | Dissolved | |
Mutual People
- The Cambridge Partnership LimitedUltrahuman Thirteen Limited, Ultrahuman Fourteen Limited, Ultrahuman Nine Limited, and 11 more are mutual companies.
- DR Kevin Stuart JohnsonUltrahuman Seven Limited, Ultrahuman Ten Limited, Ultrahuman Four Limited, and 11 more are mutual companies.
- DR James Edward ColemanUltrahuman Fourteen Limited, Ultrahuman Thirteen Limited, Granular Therapeutics Limited, and 10 more are mutual companies.
- DR William James Jonathan FinlayUltrahuman Nine Limited, Ultrahuman Twelve Limited, Granular Therapeutics Limited, and 10 more are mutual companies.
Financials, Credit Activity, Owners, and more
Completely understand the businesses you work with
Make key decisions on clients and suppliers faster, discover leads and connect with decision makers, and easily monitor opportunities that get better through time
